BILL ANALYSIS                                                                                                                                                                                                    �



                                                                  SCR 39
                                                                  Page  1



          SENATE THIRD READING
          SCR 39 (Runner)
          As Introduced  April 14, 2011
          Majority vote 

           SENATE VOTE  :38-0  
           
           RULES               11-0                                        
           
           ----------------------------------------------------------------- 
          |Ayes:|Skinner, Silva, Alejo,    |     |                          |
          |     |Butler, Carter, Mendoza,  |     |                          |
          |     |Donnelly, Hagman, Hueso,  |     |                          |
          |     |Knight, Williams          |     |                          |
          |-----+--------------------------+-----+--------------------------|
          |     |                          |     |                          |
           ----------------------------------------------------------------- 
           SUMMARY  :   Declares June 2011 as Scleroderma Awareness Month; 
          and, recognizes the efforts of health care providers, patients, 
          and scleroderma advocacy organizations to increase awareness and 
          need for research on scleroderma.  Specifically,  this resolution  
          makes the following legislative findings:

          1)Scleroderma is a chronic, disabling autoimmune disease that 
            can affect many parts of the body including skin, internal 
            organs, and blood vessels; and, patients often experience 
            damage to vital organs such as the heart, lungs, kidneys, and 
            the gastrointestinal system.

          2)An estimated 300,000 Americans suffer from scleroderma; 80% of 
            those being women; and, the total economic impact of treating 
            the disease are in excess of $1.5 billion annually, with the 
            associated morbidity cost estimated at $819,000,000 annually.

          3)Research has linked scleroderma with rheumatic disease; 
            although further research focusing on the epidemiology of 
            scleroderma is needed to increase the understanding of the 
            cause of the disease and its treatment.

          4)The designation of Scleroderma Awareness Month would recognize 
            the efforts of health care providers, patients, and 
            scleroderma advocacy organizations to increase awareness of 
            scleroderma and the need for increased research on this 








                                                                  SCR 39
                                                                  Page  2


            disease.

           FISCAL EFFECT  :   None


           Analysis Prepared by  :    Nicole Willis / RLS. / (916) 319-2800 


                                                                FN: 0001526